Your browser doesn't support javascript.
loading
A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease.
Marten, Ole; Koerber, Florian; Bloom, David; Bullinger, Monika; Buysse, Corinne; Christensen, Hannah; De Wals, Philippe; Dohna-Schwake, Christian; Henneke, Philipp; Kirchner, Markus; Knuf, Markus; Lawrenz, Burkhard; Monteiro, Andrea L; Sevilla, Joseph Patrick; Van de Velde, Nicolas; Welte, Robert; Wright, Claire; Greiner, Wolfgang.
Afiliação
  • Marten O; Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstr. 25, 33615, Bielefeld, Germany. ole.marten@uni-bielefeld.de.
  • Koerber F; GSK, Prinzregentenplatz 9, 81675, Munich, Germany.
  • Bloom D; Present Address: Institute of Health Economics and Health Care Management, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Ingolstädter Landstr. 1, 85764, Neuherberg, Germany.
  • Bullinger M; Department of Global Health and Population, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Boston, Massachusetts, 02115, USA.
  • Buysse C; Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
  • Christensen H; Department of Pediatrics, Intensive Care Unit, Erasmus Medical Center, Sophia Children's Hospital, Wytemaweg 80, 3015, CN, Rotterdam, The Netherlands.
  • De Wals P; Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK.
  • Dohna-Schwake C; Department of Social and Preventive Medicine, Laval University, Avenue de la Médecine 1050, Quebec City, G1V 0A6, Canada.
  • Henneke P; Pediatrics I, University Hospital of Essen, Hufelandstr. 55, 45147, Essen, Germany.
  • Kirchner M; Center for Pediatrics and Adolescent Medicine and Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, 79106, Freiburg, Germany.
  • Knuf M; GSK, Prinzregentenplatz 9, 81675, Munich, Germany.
  • Lawrenz B; HELIOS Dr. Horst Schmidt Kliniken, Children's Hospital, Ludwig-Erhard-Str. 100, 65199, Wiesbaden, Germany.
  • Monteiro AL; Pediatric Infectious Diseases, University Medicine, Mainz, 55131, Germany.
  • Sevilla JP; Association of Professional Pediatricians and Adolescent Medicine Specialists in Germany (Berufsverband der Kinder- und Jugendärzte e.V., BVKJ), Mielenforster Str. 2, 51069, Köln, Germany.
  • Van de Velde N; Private Practice for Pediatrics and Adolescent Medicine, Grafenstr. 80, 59821, Arnsberg, Germany.
  • Welte R; Asas Avaliacoes Economicas Em Saude Ltda ME, Rua Mario Pederneiras, 00055, APT 103 BLC II, Humaitá, Rio de Janeiro, 22261-020, Brazil.
  • Wright C; Present Address: Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
  • Greiner W; Life Sciences Group, Data for Decisions, LLC, 681 Main Street, Suite 3-37, Waltham, Massachusetts, 02451, USA.
Health Qual Life Outcomes ; 17(1): 87, 2019 May 22.
Article em En | MEDLINE | ID: mdl-31118091
ABSTRACT

BACKGROUND:

Value assessment of vaccination programs against serogroup B invasive meningococcal disease (IMD) is on the agenda of public health authorities. Current evidence on the burden due to IMD is unfit for pinning down the nature and magnitude of the full social and economic costs of IMD for two reasons. First, the concepts and components that need to be studied are not agreed, and second, measures of the concepts that have been studied are weak and inconsistent. Thus, the economic evaluation of the available serogroup B meningococcal (MenB) vaccines is difficult. The aims of this DELPHI study are to (1) agree on the concepts and components determining the burden of MenB diseases that need to be studied; and (2) seek consensus on appropriate methods and study designs to measure quality of life (QoL) associated with MenB induced long-term sequelae in future studies.

METHODS:

We designed a DELPHI questionnaire based on the findings of a recent systematic review on the QoL associated with IMD-induced long-term sequelae, and iteratively interviewed a panel of international experts, including physicians, health economists, and patient representatives. Experts were provided with a controlled feedback based on the results of the previous round.

RESULTS:

Experts reached consensus on all questions after two DELPHI rounds. Major gaps in the literature relate (i) to the classification of sequelae, which allows differentiation of severity levels, (ii) to the choice of QoL measures, and (iii) to appropriate data sources to examine long-term changes and deficits in patients' QoL.

CONCLUSIONS:

Better conceptualisation of the structure of IMD-specific sequelae and of how their diverse forms of severity might impact the QoL of survivors of IMD as well as their family network and care-providers is needed to generate relevant, reliable and generalisable data on QoL in the future. The results of this DELPHI panel provide useful guidance on how to choose the study design, target population and appropriate QoL measures for future research and hence, help promote the appropriateness and consistency in study methodology and sample characteristics.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Carga Global da Doença / Infecções Meningocócicas Tipo de estudo: Systematic_reviews Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Carga Global da Doença / Infecções Meningocócicas Tipo de estudo: Systematic_reviews Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article